Psylo leverages CDD Vault to ramp up psychedelic drug discovery

In this case study, Collaborative Drug Discovery discusses Psylo's utilization of the CDD Vault^® registration system and ELN. Psylo, a company focused on developing new drugs for psychiatric disorders, has adopted these platforms as its central repository. These systems help Psylo store, characterize, and manage its libraries, structure activity relationship (SAR) data, as well as in vitro and other experimental and screening assay data. Psylo's approach involves redesigning existing families of psychedelic compounds into entirely new chemical entities (NCEs) for its drug portfolio.